

PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

PLN
DNC
T&B

To: FISH & RICHARDSON P.C. Attn. Myers, Louis P. 225 Franklin Street Boston, Mass. 02110-2804 UNITED STATES OF AMERICA	RECEIVED	NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT OR THE DECLARATION
---	-----------------	---

007 01 2001

FISH & RICHARDSON, P.C.
BOSTON OFFICE

(PCT Rule 44.1)

Date of mailing
(day/month/year)

27/09/2001

Applicant's or agent's file reference 10797-004W01	FOR FURTHER ACTION	See paragraphs 1 and 4 below
International application No. PCT/US 01/ 06356	International filing date (day/month/year)	28/02/2001
Applicant BOSTON HEART FOUNDATION, INC		

1. The applicant is hereby notified that the International Search Report has been established and is transmitted herewith.

Filing of amendments and statement under Article 19:

The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.

Where? Directly to the International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland
Facsimile No.: (41-22) 740.14.35

Docketed By Billing Secretary	
Due Date:	
Deadline:	
Initials:	PL

For more detailed instructions, see the notes on the accompanying sheet.

2. The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

PCT/ISA/2001
Annex 1
12/2001

3. With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.

Ref ID: *PL*

no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. Further action(s): The applicant is reminded of the following:

Shortly after 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

Within 19 months from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the International Searching Authority  European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Sandra De Jong-van Dam
---	--

NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When? Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been filed, see below.

How? Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

1. [Where originally there were 48 claims and after amendment of some claims there are 51]:
"Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
2. [Where originally there were 15 claims and after amendment of all claims there are 11]:
"Claims 1 to 15 replaced by amended claims 1 to 11."
3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
"Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or
"Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
4. [Where various kinds of amendments are made]:
"Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international application is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Office, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 10797-004W01	FOR FURTHER ACTION	see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.
International application No. PCT/US 01/ 06356	International filing date (day/month/year) 28/02/2001	(Earliest) Priority Date (day/month/year) 02/03/2000
Applicant BOSTON HEART FOUNDATION, INC		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 12 sheets.

It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
- the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).
- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :
- contained in the international application in written form.
- filed together with the international application in computer readable form.
- furnished subsequently to this Authority in written form.
- furnished subsequently to this Authority in computer readable form.
- the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. **Certain claims were found unsearchable** (See Box I).

3. **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

- the text is approved as submitted by the applicant.
- the text has been established by this Authority to read as follows:

**LOW DENSITY LIPROTEIN BINDING PROTEINS AND THEIR USE IN DIAGNOSING AND
TREATING ATHEROSCLEROSIS**

5. With regard to the **abstract**,

- the text is approved as submitted by the applicant.
- the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

- as suggested by the applicant.
- because the applicant failed to suggest a figure.
- because this figure better characterizes the invention.

None of the figures.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 01/06356

Box III TEXT OF THE ABSTRACT (Continuation of item 5 of the first sheet)

Delete word "nove!" on line 1.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/06356

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7	C12N15/12	C07K14/47	C07K7/08	C07K16/18	C12Q1/68
	A61K38/04	A61K38/17	A61K39/00	G01N33/53	G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K C12Q A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBL, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	<p>WO 98 23282 A (BOSTON HEART FOUNDATION INC) 4 June 1998 (1998-06-04) the whole document ---</p> <p style="text-align: center;">-/-</p>	1-22,24, 26-32, 34-37



Further documents are listed in the continuation of box C.



Patent family members are listed in annex

° Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

14 September 2001

27/09/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

van de Kamp, M

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/06356

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DATABASE EM_HUM 'Online! EMBL; ID HSAF6088, AC AF006088, 29 July 1997 (1997-07-29)</p> <p>WELCH M D ET AL.: "Homo sapiens Arp2/3 protein complex subunit p16-Arc (ARC16) mRNA, complete cds" XP002177049</p> <p>Note: 99.4% nt seq identity with SEQ ID NO:15 in 1833 nt overlap (1-1831:94-1925), 100.0% aa seq identity with SEQ ID NO:6 in 151 aa overlap (1-151:1-151) the whole document</p> <p>-& WELCH M D ET AL.: "The human Arp2/3 complex is composed of evolutionary conserved subunits and is localized to cellular regions of dynamic actin filament assembly"</p> <p>JOURNAL OF CELL BIOLOGY, vol. 138, no. 2, 28 July 1997 (1997-07-28), pages 375-384, XP002177045</p> <p>abstract</p> <p>figure 1</p> <p>---</p> <p>WO 94 16074 A (UNIV ST LOUIS ;US HEALTH (US); FAUCI ANTHONY S (US); FORD RICHARD) 21 July 1994 (1994-07-21)</p> <p>Note: 99.2% (74.4%) nt seq identity of SEQ ID NO:1 with SEQ ID NO:46 (14) in 1021 (1860) nt overlap (781-1799:1638-621 (2-1799:2480-681))</p> <p>example 1</p> <p>page 75-76</p> <p>claim 4</p> <p>---</p> <p>WO 91 06011 A (UNIV LEHIGH) 2 May 1991 (1991-05-02)</p> <p>page 2, line 17 -page 3, line 14</p> <p>page 9, line 20 -page 13, line 22</p> <p>claims 1-9</p> <p>---</p> <p>EP 0 586 094 A (WISCONSIN ALUMNI RES FOUND) 9 March 1994 (1994-03-09)</p> <p>page 4, line 33-54</p> <p>page 6, line 4-31</p> <p>---</p> <p>DE 42 22 385 A (BOEHRINGER INGELHEIM INT) 13 January 1994 (1994-01-13)</p> <p>column 2, line 23-35</p> <p>example 3</p> <p>claims 1-8</p> <p>---</p> <p>-/-</p>	1,2,6, 10,11, 13,14
A	WO 94 16074 A (UNIV ST LOUIS ;US HEALTH (US); FAUCI ANTHONY S (US); FORD RICHARD) 21 July 1994 (1994-07-21)	1,5,8
A	WO 91 06011 A (UNIV LEHIGH) 2 May 1991 (1991-05-02)	
A	EP 0 586 094 A (WISCONSIN ALUMNI RES FOUND) 9 March 1994 (1994-03-09)	
A	DE 42 22 385 A (BOEHRINGER INGELHEIM INT) 13 January 1994 (1994-01-13)	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/06356

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 773 290 A (KOWA CO) 14 May 1997 (1997-05-14) page 3, line 12-18 examples 1-7 ---	
A	TKACHUK V A ET AL.: "Identification of an atypical lipoprotein-binding protein from human aortic smooth muscle as T-cadherin" FEBS LETTERS, vol. 421, no. 3, 16 January 1998 (1998-01-16), pages 208-212, XP002177046 abstract figure 1 ---	
A	KUZMENKO Y S ET AL.: "Characteristics of smooth muscle cell lipoprotein binding proteins (p105/p130) as T-cadherin and regulation by positive and negative growth regulators." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 246, no. 2, 19 May 1998 (1998-05-19), pages 489-494, XP002177047 ISSN: 0006-291X abstract figures 1-5 ---	
A	RAMPRASAD M P ET AL.: "Cell surface expression of mouse macrosialin and human CD68 and their role as macrophage receptors for oxidized low density lipoprotein." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 93, no. 25, 1996, pages 14833-14838, XP002177048 1996 ISSN: 0027-8424 abstract figures 3,6 ---	
A	LEES A M ET AL.: "99M Technetium-labeled low density lipoprotein: receptor recognition and intracellular sequestration of radiolabel" JOURNAL OF LIPID RESEARCH, vol. 32, no. 1, January 1991 (1991-01), pages 1-8, XP001002803 ISSN: 0022-2275 abstract page 1, left-hand column, line 1 -right-hand column, line 10 -----	

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1,2,9-37 (all partially); 3 (completely)

An isolated polynucleotide encoding a polypeptide comprising the amino acid (aa) sequence of SEQ ID NO:1 or 9, or a polynucleotide capable of hybridizing to it which is at least 95% identical and wherein the encoded polypeptide is capable of binding to LDL, or a polynucleotide encoding a polypeptide comprising an aa sequence with at least 90% sequence identity with the aa sequence of SEQ ID NO:1 or 9 and capable of binding to LDL, or a biologically active fragment of any of these polynucleotides wherein the encoded polypeptide is capable of binding to LDL. A polynucleotide as said encoding a polypeptide comprising the aa residues 14-43 (SEQ ID NO:23) or 38-43 (SEQ ID NO:24) of the aa sequence of SEQ ID NO:1, or a polynucleotide capable of hybridizing to it which is at least 95% identical and wherein the encoded polypeptide is capable of binding to LDL, or a biologically active fragment thereof wherein the encoded polypeptide is capable of binding to LDL. A polynucleotide as said comprising the nucleic acid of SEQ ID NO:10. A recombinant vector comprising a polynucleotide as said, a cell comprising said vector, and a method for producing an LDL binding protein (LBP) comprising culturing said cell. An isolated polypeptide having the aa sequence of SEQ ID NO:1 or 9, or a polypeptide which is at least 95% identical to said polypeptide and capable of binding to LDL, or a biologically active fragment of said polypeptide capable of binding to LDL. A polypeptide as said having the aa residues 14-43 (SEQ ID NO:23) or 38-43 (SEQ ID NO:24) of the aa sequence of SEQ ID NO:1, or a polypeptide which is at least 95% identical and capable of binding to LDL, or a biologically active fragment thereof capable of binding to LDL. Methods of use of (said) LBP polypeptides in determination of risk for arteriosclerosis, and in the evaluation of agents for treatment of arteriosclerosis, of agents for the ability to alter binding of LBP polypeptide to a binding molecule, or of agents for the ability to bind to an LBP polypeptide or to a nucleic acid encoding an LBP regulatory sequence, and agents identified therewith. Methods of treatment, diagnosis and immunization. Pharmaceutical and vaccine compositions. Methods of making LBP fragments and analogs.

2. Claims: 1,2,9-37 (all partially); 4 (completely)

An isolated polynucleotide encoding a polypeptide comprising the amino acid (aa) sequence of SEQ ID NO:2-4 or 47, or a polynucleotide capable of hybridizing to it which is at least 95% identical and wherein the encoded polypeptide is capable of binding to LDL, or a polynucleotide encoding a polypeptide comprising an aa sequence with at least 90%

FURTHER INFORMATION CONTINUED FROM PCT/USA/ 210

sequence identity with the aa sequence of SEQ ID NO:2-4 or 47 and capable of binding to LDL, or a biologically active fragment of any of these polynucleotides wherein the encoded polypeptide is capable of binding to LDL. A polynucleotide as said encoding a polypeptide comprising the aa residues 338-353, 338-365, 354-365 or 444-453 (SEQ ID NOs 25-28) of the aa sequence of SEQ ID NO:47, or a polynucleotide capable of hybridizing to it which is at least 95% identical and wherein the encoded polypeptide is capable of binding to LDL, or a biologically active fragment thereof wherein the encoded polypeptide is capable of binding to LDL. A polynucleotide as said comprising the nucleic acid of SEQ ID NO:48. A recombinant vector comprising a polynucleotide as said, a cell comprising said vector, and a method for producing an LDL binding protein (LBP) comprising culturing said cell. An isolated polypeptide having the aa sequence of SEQ ID NO:2-4 or 47, or a polypeptide which is at least 95% identical to said polypeptide and capable of binding to LDL, or a biologically active fragment of said polypeptide capable of binding to LDL. A polypeptide as said having the aa residues 338-353, 338-365, 354-365 or 444-453 (SEQ ID NOs 25-28) of the aa sequence of SEQ ID NO:47, or a polypeptide which is at least 95% identical and capable of binding to LDL, or a biologically active fragment thereof capable of binding to LDL. Methods of use of (said) LBP polypeptides in determination of risk for arteriosclerosis, and in the evaluation of agents for treatment of arteriosclerosis, of agents for the ability to alter binding of LBP polypeptide to a binding molecule, or of agents for the ability to bind to an LBP polypeptide or to a nucleic acid encoding an LBP regulatory sequence, and agents identified therewith. Methods of treatment, diagnosis and immunization. Pharmaceutical and vaccine compositions. Methods of making LBP fragments and analogs.

3. Claims: 1,2,9-37 (all partially); 5 (completely)

An isolated polynucleotide encoding a polypeptide comprising the amino acid (aa) sequence of SEQ ID NO:5, or a polynucleotide capable of hybridizing to it which is at least 95% identical and wherein the encoded polypeptide is capable of binding to LDL, or a polynucleotide encoding a polypeptide comprising an aa sequence with at least 90% sequence identity with the aa sequence of SEQ ID NO:5 and capable of binding to LDL, or a biologically active fragment of any of these polynucleotides wherein the encoded polypeptide is capable of binding to LDL. A polynucleotide as said encoding a polypeptide comprising the aa residues 96-110 (SEQ ID NO:29) of the aa sequence of SEQ ID NO:5, or a polynucleotide capable of hybridizing to it which is at least 95% identical and wherein the encoded polypeptide is capable of binding to LDL, or a biologically active fragment thereof wherein the encoded polypeptide is capable of binding to LDL. A polynucleotide as said comprising the

FURTHER INFORMATION CONTINUED FROM PCT/USA/ 210

nucleic acid of SEQ ID NO:14. A recombinant vector comprising a polynucleotide as said, a cell comprising said vector, and a method for producing an LDL binding protein (LBP) comprising culturing said cell. An isolated polypeptide having the aa sequence of SEQ ID NO:5, or a polypeptide which is at least 95% identical to said polypeptide and capable of binding to LDL, or a biologically active fragment of said polypeptide capable of binding to LDL. A polypeptide as said having the aa residues 96-110 (SEQ ID NO:29) of the aa sequence of SEQ ID NO:5, or a polypeptide which is at least 95% identical and capable of binding to LDL, or a biologically active fragment thereof capable of binding to LDL. Methods of use of (said) LBP polypeptides in determination of risk for arteriosclerosis, and in the evaluation of agents for treatment of arteriosclerosis, of agents for the ability to alter binding of LBP polypeptide to a binding molecule, or of agents for the ability to bind to an LBP polypeptide or to a nucleic acid encoding an LBP regulatory sequence, and agents identified therewith. Methods of treatment, diagnosis and immunization. Pharmaceutical and vaccine compositions. Methods of making LBP fragments and analogs.

4. Claims: 1,2,9-37 (all partially); 6 (completely)

An isolated polynucleotide encoding a polypeptide comprising the amino acid (aa) sequence of SEQ ID NO:6 or 9, or a polynucleotide capable of hybridizing to it which is at least 95% identical and wherein the encoded polypeptide is capable of binding to LDL, or a polynucleotide encoding a polypeptide comprising an aa sequence with at least 90% sequence identity with the aa sequence of SEQ ID NO:6 or 9 and capable of binding to LDL, or a biologically active fragment of any of these polynucleotides wherein the encoded polypeptide is capable of binding to LDL. A polynucleotide as said encoding a polypeptide comprising the aa residues 14-43 (SEQ ID NO:23) or 38-43 (SEQ ID NO:24) of the aa sequence of SEQ ID NO:6, or a polynucleotide capable of hybridizing to it which is at least 95% identical and wherein the encoded polypeptide is capable of binding to LDL, or a biologically active fragment thereof wherein the encoded polypeptide is capable of binding to LDL. A polynucleotide as said comprising the nucleic acid of SEQ ID NO:15. A recombinant vector comprising a polynucleotide as said, a cell comprising said vector, and a method for producing an LDL binding protein (LBP) comprising culturing said cell. An isolated polypeptide having the aa sequence of SEQ ID NO:6 or 9, or a polypeptide which is at least 95% identical to said polypeptide and capable of binding to LDL, or a biologically active fragment of said polypeptide capable of binding to LDL. A polypeptide as said having the aa residues 14-43 (SEQ ID NO:23) or 38-43 (SEQ ID NO:24) of the aa sequence of SEQ ID NO:6, or a polypeptide which is at least 95% identical and capable of binding to LDL, or a

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

biologically active fragment thereof capable of binding to LDL. Methods of use of (said) LBP polypeptides in determination of risk for arteriosclerosis, and in the evaluation of agents for treatment of arteriosclerosis, of agents for the ability to alter binding of LBP polypeptide to a binding molecule, or of agents for the ability to bind to an LBP polypeptide or to a nucleic acid encoding an LBP regulatory sequence, and agents identified therewith. Methods of treatment, diagnosis and immunization. Pharmaceutical and vaccine compositions. Methods of making LBP fragments and analogs.

5. Claims: 1,2,9-37 (all partially); 7 (completely)

An isolated polynucleotide encoding a polypeptide comprising the amino acid (aa) sequence of SEQ ID NO:7 or 43, or a polynucleotide capable of hybridizing to it which is at least 95% identical and wherein the encoded polypeptide is capable of binding to LDL, or a polynucleotide encoding a polypeptide comprising an aa sequence with at least 90% sequence identity with the aa sequence of SEQ ID NO:7 or 43 and capable of binding to LDL, or a biologically active fragment of any of these polynucleotides wherein the encoded polypeptide is capable of binding to LDL. A polynucleotide as said encoding a polypeptide comprising the aa residues 329-343, 329-354, 344-354 or 529-538 (SEQ ID NOs 19-22) of the aa sequence of SEQ ID NO:43, or a polynucleotide capable of hybridizing to it which is at least 95% identical and wherein the encoded polypeptide is capable of binding to LDL, or a biologically active fragment thereof wherein the encoded polypeptide is capable of binding to LDL. A polynucleotide as said comprising the nucleic acid of SEQ ID NO:45. A recombinant vector comprising a polynucleotide as said, a cell comprising said vector, and a method for producing an LDL binding protein (LBP) comprising culturing said cell. An isolated polypeptide having the aa sequence of SEQ ID NO:7 or 43, or a polypeptide which is at least 95% identical to said polypeptide and capable of binding to LDL, or a biologically active fragment of said polypeptide capable of binding to LDL. A polypeptide as said having the aa residues 329-343, 329-354, 344-354 or 529-538 (SEQ ID NOs 19-22) of the aa sequence of SEQ ID NO:43, or a polypeptide which is at least 95% identical and capable of binding to LDL, or a biologically active fragment thereof capable of binding to LDL. Methods of use of (said) LBP polypeptides in determination of risk for arteriosclerosis, and in the evaluation of agents for treatment of arteriosclerosis, of agents for the ability to alter binding of LBP polypeptide to a binding molecule, or of agents for the ability to bind to an LBP polypeptide or to a nucleic acid encoding an LBP regulatory sequence, and agents identified therewith. Methods of treatment, diagnosis and immunization. Pharmaceutical and vaccine compositions. Methods of making LBP fragments and analogs.

FURTHER INFORMATION CONTINUED FROM PCT/USA/ 210

6. Claims: 1,2,9-37 (all partially); 8 (completely)

An isolated polynucleotide encoding a polypeptide comprising the amino acid (aa) sequence of SEQ ID NO:8 or 44, or a polynucleotide capable of hybridizing to it which is at least 95% identical and wherein the encoded polypeptide is capable of binding to LDL, or a polynucleotide encoding a polypeptide comprising an aa sequence with at least 90% sequence identity with the aa sequence of SEQ ID NO:8 or 44 and capable of binding to LDL, or a biologically active fragment of any of these polynucleotides wherein the encoded polypeptide is capable of binding to LDL. A polynucleotide as said encoding a polypeptide comprising the aa residues 69-75 (SEQ ID NO:41) of the aa sequence of SEQ ID NO:44, or a polynucleotide capable of hybridizing to it which is at least 95% identical and wherein the encoded polypeptide is capable of binding to LDL, or a biologically active fragment thereof wherein the encoded polypeptide is capable of binding to LDL. A polynucleotide as said comprising the nucleic acid of SEQ ID NO:46. A recombinant vector comprising a polynucleotide as said, a cell comprising said vector, and a method for producing an LDL binding protein (LBP) comprising culturing said cell. An isolated polypeptide having the aa sequence of SEQ ID NO:8 or 44, or a polypeptide which is at least 95% identical to said polypeptide and capable of binding to LDL, or a biologically active fragment of said polypeptide capable of binding to LDL. A polypeptide as said having the aa residues 69-75 (SEQ ID NO:41) of the aa sequence of SEQ ID NO:44, or a polypeptide which is at least 95% identical and capable of binding to LDL, or a biologically active fragment thereof capable of binding to LDL. Methods of use of (said) LBP polypeptides in determination of risk for arteriosclerosis, and in the evaluation of agents for treatment of arteriosclerosis, of agents for the ability to alter binding of LBP polypeptide to a binding molecule, or of agents for the ability to bind to an LBP polypeptide or to a nucleic acid encoding an LBP regulatory sequence, and agents identified therewith. Methods of treatment, diagnosis and immunization. Pharmaceutical and vaccine compositions. Methods of making LBP fragments and analogs.

FURTHER INFORMATION CONTINUED FROM PCT/USA/ 210

Continuation of Box I.1

Remark 1: Although claims 15, 16 and 33 (as far as in vivo methods are concerned) are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Remark 2: Although claims 17, 18, 26-29, 34, 36 and 37 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.2

Claims Nos.: 23, 25, 33

Remark 3: Claims not searched: 23, 25, 33. Claims searched incompletely: 19, 26, 28-30, 32. Present claims 23, 25 and 33 relate to agents defined by reference to a desirable characteristic or property, namely the capacity to bind to LBP or to a nucleic acid encoding an LBP regulatory sequence. Present claims 19, 26, 28-30 and 32 relate to agents defined by reference to a desirable characteristic or property, namely the capacity to have an effect on an aspect of LBP structure or metabolism. The claims cover all agents having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compounds by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of claims 19, 26, 28-30 and 32 which appear to be clear, supported and disclosed, namely those parts relating to the compounds defined by claims 1-9, 13 and 14.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 01/06356

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. Claims Nos.: 23, 25, 33
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/06356

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9823282	A	04-06-1998	AU AU EP JP WO	736142 B2 7408898 A 0969855 A1 2001506983 T 9823282 A1	26-07-2001 22-06-1998 12-01-2000 29-05-2001 04-06-1998
WO 9416074	A	21-07-1994	AU WO	6234194 A 9416074 A2	15-08-1994 21-07-1994
WO 9106011	A	02-05-1991	US AU EP JP WO	5135848 A 6641690 A 0497881 A1 5504196 T 9106011 A1	04-08-1992 16-05-1991 12-08-1992 01-07-1993 02-05-1991
EP 0586094	A	09-03-1994	EP JP US	0586094 A1 6087895 A 5521071 A	09-03-1994 29-03-1994 28-05-1996
DE 4222385	A	13-01-1994	DE AU AU CA CN WO EP FI HU JP MX NO NZ ZA	4222385 A1 678978 B2 4564093 A 2117099 A1 1082609 A 9401553 A1 0613498 A1 941077 A 68246 A2 6510673 T 9304074 A1 940797 A 254102 A 9304873 A	13-01-1994 19-06-1997 31-01-1994 20-01-1994 23-02-1994 20-01-1994 07-09-1994 08-03-1994 28-06-1995 01-12-1994 31-05-1994 07-03-1994 22-08-1997 18-01-1994
EP 0773290	A	14-05-1997	JP EP US	9163988 A 0773290 A2 5665872 A	24-06-1997 14-05-1997 09-09-1997